---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-175095"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:11:16.937138+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AlloVir prices public offering of 20M shares at $3.75/share for $75M gross

## Summary
- Priced underwritten public offering of 20,000,000 shares at $3.75 per share; gross proceeds of $75.0M.
- Net proceeds estimated at $70.2M ($80.7M if underwriters fully exercise 30-day option for 3M additional shares).
- Offering expected to close on or about June 26, 2023; underwriters include J.P. Morgan, Morgan Stanley, and BofA.
- Shares offered under existing shelf registration; 90-day lock-up for AlloVir executives and directors.

## SEC filing metadata
- accession: 0001193125-23-175095
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523175095/0001193125-23-175095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523175095/d472315d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-175095
- JSON: https://secwatch.observer/filing/0001193125-23-175095.json
- Plain text: https://secwatch.observer/filing/0001193125-23-175095.txt

## Key facts
- Material Agreements
  Kalaris Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters valued at $3.75 per share (effective 2023-06-21).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters
  - Value: $3.75 per share
  - Effective: 2023-06-21
  source text: On June 21, 2023, AlloVir, Inc. (“AlloVir”) entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BoFA Securities, Inc., as the representatives of the several underwriters (the “Underwriters”) relating to an underwritten public offering of 20,000,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $3.75 per share, less underwriting discounts and commissions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523175095/0001193125-23-175095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.